Seltorexant is a Small Molecule owned by Johnson & Johnson, and is involved in 35 clinical trials, of which 27 were completed, 7 are ongoing, and 1 is planned.
Seltorexant (JNJ-7922, JNJ-42847922, MIN-202) is a selective orexin-2 receptor antagonist. Orexin maintain a long, consolidated waking period by activating waking monoaminergic and cholinergic neurons in the hypothalamus and brainstem regions. Orexin-2 receptor mediate both excitatory and inhibitory signals depending on the postsynaptic neurons. Orexins through orexin receptors are also involved in the regulation of the sleep-wake cycle. MIN-202 blocks orexin 2 receptor and reduces the neurotransmitters level that signal the brain to maintain vigilance and wakefulness.
The revenue for Seltorexant is expected to reach a total of $3.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Seltorexant NPV Report.
Seltorexant is originated and owned by Johnson & Johnson.
Seltorexant (JNJ-7922, JNJ-42847922, MIN-202) is under development for the treatment of major depressive disorder (MDD), Alzheimer’s disease (AD), and primary and secondary insomnia. It is administered orally as a capsule, film coated tablet and intravenous route. The drug candidate acts by targeting orexin-2 receptor. It is a new molecular entity (NME).
Johnson & Johnson Overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.
Quick View – Seltorexant
|Highest Development Stage|